Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a sell rating to a hold rating in a report released on Saturday morning.

A number of other equities analysts also recently commented on ARTV. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Artiva Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $18.67.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $7.29 on Friday. The firm has a market cap of $180.21 million, a PE ratio of -2.13 and a beta of 1.46. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $7.75. The business has a 50 day moving average price of $5.19 and a 200-day moving average price of $4.33.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.03. Research analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics in the third quarter worth $41,000. Bank of America Corp DE raised its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics in the second quarter worth $53,000. Qube Research & Technologies Ltd bought a new position in Artiva Biotherapeutics in the second quarter worth $58,000. Finally, Jane Street Group LLC bought a new position in Artiva Biotherapeutics in the second quarter worth $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.